<?xml version='1.0' encoding='utf-8'?>
<document id="12549947"><sentence text="Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction."><entity charOffset="38-47" id="DDI-PubMed.12549947.s1.e0" text="ritonavir" /></sentence><sentence text="To report a case of Parkinson-like symptoms appearing in a patient after introduction of ritonavir to buspirone therapy"><entity charOffset="89-98" id="DDI-PubMed.12549947.s2.e0" text="ritonavir" /><entity charOffset="102-111" id="DDI-PubMed.12549947.s2.e1" text="buspirone" /><pair ddi="false" e1="DDI-PubMed.12549947.s2.e0" e2="DDI-PubMed.12549947.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12549947.s2.e0" e2="DDI-PubMed.12549947.s2.e1" /></sentence><sentence text="" /><sentence text="A 54-year-old HIV-positive white man presented to the clinic with a 2-week history of ataxia, shuffling gait, cogwheel rigidity, resting tremor, and sad affect with masked features" /><sentence text=" This patient had been receiving high-dose buspirone (40 mg every morning and 30 mg every evening) for 2 years prior to the introduction of ritonavir/indinavir combination therapy (400 mg/400 mg twice daily) 6 weeks prior to initiation of the above symptoms"><entity charOffset="43-52" id="DDI-PubMed.12549947.s5.e0" text="buspirone" /><entity charOffset="140-149" id="DDI-PubMed.12549947.s5.e1" text="ritonavir" /><entity charOffset="150-159" id="DDI-PubMed.12549947.s5.e2" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.12549947.s5.e0" e2="DDI-PubMed.12549947.s5.e0" /><pair ddi="false" e1="DDI-PubMed.12549947.s5.e0" e2="DDI-PubMed.12549947.s5.e1" /><pair ddi="false" e1="DDI-PubMed.12549947.s5.e0" e2="DDI-PubMed.12549947.s5.e2" /><pair ddi="false" e1="DDI-PubMed.12549947.s5.e1" e2="DDI-PubMed.12549947.s5.e1" /><pair ddi="false" e1="DDI-PubMed.12549947.s5.e1" e2="DDI-PubMed.12549947.s5.e2" /></sentence><sentence text=" Buspirone was decreased to 15 mg 3 times daily, ritonavir/indinavir was discontinued, and amprenavir 1200 mg twice daily was added"><entity charOffset="1-10" id="DDI-PubMed.12549947.s6.e0" text="Buspirone" /><entity charOffset="49-58" id="DDI-PubMed.12549947.s6.e1" text="ritonavir" /><entity charOffset="59-68" id="DDI-PubMed.12549947.s6.e2" text="indinavir" /><entity charOffset="91-101" id="DDI-PubMed.12549947.s6.e3" text="amprenavir" /><pair ddi="false" e1="DDI-PubMed.12549947.s6.e0" e2="DDI-PubMed.12549947.s6.e0" /><pair ddi="false" e1="DDI-PubMed.12549947.s6.e0" e2="DDI-PubMed.12549947.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12549947.s6.e0" e2="DDI-PubMed.12549947.s6.e2" /><pair ddi="false" e1="DDI-PubMed.12549947.s6.e0" e2="DDI-PubMed.12549947.s6.e3" /><pair ddi="false" e1="DDI-PubMed.12549947.s6.e1" e2="DDI-PubMed.12549947.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12549947.s6.e1" e2="DDI-PubMed.12549947.s6.e2" /><pair ddi="false" e1="DDI-PubMed.12549947.s6.e1" e2="DDI-PubMed.12549947.s6.e3" /><pair ddi="false" e1="DDI-PubMed.12549947.s6.e2" e2="DDI-PubMed.12549947.s6.e2" /><pair ddi="false" e1="DDI-PubMed.12549947.s6.e2" e2="DDI-PubMed.12549947.s6.e3" /></sentence><sentence text=" The patient's symptoms began to subside after 1 week, with complete resolution after about 2 weeks" /><sentence text=" The patient continued to receive buspirone for an additional 12 months without recurrence of symptoms"><entity charOffset="34-43" id="DDI-PubMed.12549947.s8.e0" text="buspirone" /></sentence><sentence text="" /><sentence text="This is the first reported interaction of buspirone and antiretrovirals"><entity charOffset="42-51" id="DDI-PubMed.12549947.s10.e0" text="buspirone" /></sentence><sentence text=" Buspirone, extensively metabolized by CYP3A4, was likely at supratherapeutic levels due to the inhibitory effect of ritonavir and, secondarily, indinavir"><entity charOffset="1-10" id="DDI-PubMed.12549947.s11.e0" text="Buspirone" /><entity charOffset="117-126" id="DDI-PubMed.12549947.s11.e1" text="ritonavir" /><entity charOffset="145-154" id="DDI-PubMed.12549947.s11.e2" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.12549947.s11.e0" e2="DDI-PubMed.12549947.s11.e0" /><pair ddi="false" e1="DDI-PubMed.12549947.s11.e0" e2="DDI-PubMed.12549947.s11.e1" /><pair ddi="false" e1="DDI-PubMed.12549947.s11.e0" e2="DDI-PubMed.12549947.s11.e2" /><pair ddi="false" e1="DDI-PubMed.12549947.s11.e1" e2="DDI-PubMed.12549947.s11.e1" /><pair ddi="false" e1="DDI-PubMed.12549947.s11.e1" e2="DDI-PubMed.12549947.s11.e2" /></sentence><sentence text=" The Parkinson-like symptoms developed rapidly and severely, impacted this patient's quality of life, and necessitated significant clinic expenditures to identify this drug-drug interaction" /><sentence text="" /><sentence text="This case demonstrates a severe drug-drug interaction between buspirone and ritonavir and further demonstrates the need for awareness of the metabolic profile for all agents an HIV-infected patient is receiving"><entity charOffset="62-71" id="DDI-PubMed.12549947.s14.e0" text="buspirone" /><entity charOffset="76-85" id="DDI-PubMed.12549947.s14.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.12549947.s14.e0" e2="DDI-PubMed.12549947.s14.e0" /><pair ddi="false" e1="DDI-PubMed.12549947.s14.e0" e2="DDI-PubMed.12549947.s14.e1" /></sentence><sentence text="" /></document>